wild type ATTR amyloidosis

disease
On this page

Also known as ATTRwt amyloidosisATTRwt-related amyloidosisSenile systemic amyloidosisSSAwild type ATTR-related amyloidosis

Summary

wild type ATTR amyloidosis (MONDO:0018018) is a disease and 5 clinical trials. Top therapeutic interventions include patisiran. A subtype of non-familial restrictive cardiomyopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: 1-5 / 10 000 (Worldwide) [Orphanet-validated]
  • Phenotypes (HPO): 32
  • Clinical trials: 5

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Point prevalence1-5 / 10 0001.72WorldwideValidated

Signs & symptoms

Clinical features (HPO)

32 HPO clinical features (Orphanet curated; top 32 by frequency):

HPO IDTermFrequency
HP:0001635Congestive heart failureVery frequent (80-99%)
HP:0001639Hypertrophic cardiomyopathyVery frequent (80-99%)
HP:0001658Myocardial infarctionVery frequent (80-99%)
HP:0002202Pleural effusionVery frequent (80-99%)
HP:0003115Abnormal EKGVery frequent (80-99%)
HP:0006530Abnormal pulmonary interstitial morphologyVery frequent (80-99%)
HP:0010741Pedal edemaVery frequent (80-99%)
HP:0031327Transthyretin cardiac amyloidosisVery frequent (80-99%)
HP:0100598Pulmonary edemaVery frequent (80-99%)
HP:0000763Sensory neuropathyFrequent (30-79%)
HP:0002028Chronic diarrheaFrequent (30-79%)
HP:0002240HepatomegalyFrequent (30-79%)
HP:0002254Intermittent diarrheaFrequent (30-79%)
HP:0002495Impaired vibratory sensationFrequent (30-79%)
HP:0002579Gastrointestinal dysmotilityFrequent (30-79%)
HP:0002607Bowel incontinenceFrequent (30-79%)
HP:0003155Elevated circulating alkaline phosphatase concentrationFrequent (30-79%)
HP:0004926Orthostatic hypotension due to autonomic dysfunctionFrequent (30-79%)
HP:0005110Atrial fibrillationFrequent (30-79%)
HP:0005341Autonomic bladder dysfunctionFrequent (30-79%)
HP:0011675ArrhythmiaFrequent (30-79%)
HP:0012185Constrictive median neuropathyFrequent (30-79%)
HP:0012332Abnormal autonomic nervous system physiologyFrequent (30-79%)
HP:0200101Decreased/absent ankle reflexesFrequent (30-79%)
HP:0000083Renal insufficiencyOccasional (5-29%)
HP:0000093ProteinuriaOccasional (5-29%)
HP:0000100Nephrotic syndromeOccasional (5-29%)
HP:0000112NephropathyOccasional (5-29%)
HP:0001650Aortic valve stenosisOccasional (5-29%)
HP:0001662BradycardiaOccasional (5-29%)
HP:0001824Weight lossOccasional (5-29%)
HP:0003416Spinal canal stenosisOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical namewild type ATTR amyloidosis
Mondo IDMONDO:0018018
Orphanet330001
DOIDDOID:0080937
ICD-10-CME85.82
ICD-1125699053
SNOMED CT237877004
UMLSC0342623
MedGen87446
GARD0021501
Is cancer (heuristic)no

Also known as: ATTRwt amyloidosis · ATTRwt-related amyloidosis · Senile systemic amyloidosis · SSA · wild type ATTR-related amyloidosis

Disease family

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disordermuscle tissue disordercardiomyopathyintrinsic cardiomyopathyrestrictive cardiomyopathy › non-familial restrictive cardiomyopathy › wild type ATTR amyloidosis

Related subtypes (6): cardiac sarcoidosis, hypereosinophilic syndrome, tropical endomyocardial fibrosis, Loeffler endocarditis, AL amyloidosis, AA amyloidosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified4
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05023889EARLY_PHASE1COMPLETEDSpectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
NCT07314268Not specifiedRECRUITINGATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers
NCT01604122Not specifiedCOMPLETEDBurden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers
NCT02792790Not specifiedCOMPLETEDCarpal Tunnel Syndrome and Amyloid Cardiomyopathy
NCT06261216Not specifiedCOMPLETEDAssociation Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
PATISIRAN31